Randomized trial in postmenopausal women with estrogen receptor-positive, HER2-negative breast cancer in the presurgical setting to test whether the addition of GDC-0032 to letrozole gives added benefit Randomizovaná studie u postmenopauzálních žen s ER pozitivním/ HER2 negativním nádorem prsu ověřující přínos kombinované předoperační léčby GDC-0032 a Letrozolu The primary objective of this study is to evaluate the efficacy of letrozole plus GDC-0032 versus letrozole plus placebo in women with ER+/HER2- early stage breast cancer, as measured by the following...

• Country None
• organs None
• Specialty None

Study of the novel cancer drug GDC-0941 (or placebo) in combination with : a) the approved anticancer drugs carboplatin and paclitaxel; and b) the approved anticancer drugs carboplatin, paclitaxel and bevacizumab in previously untreated patients with advanced non-small cell lung cancer Part I •To evaluate the efficacy (as measured by PFS) of GDC-0941 340mg+carboplatin+paclitaxel (Arm A) versus carboplatin+paclitaxel (Arm B) in all patients with squamous NSCLC •To evaluate the effi...

• Country None
• organs None
• Specialty None

A Study of the Safety and Efficacy of GDC 0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus To evaluate the clinical efficacy of GDC-0853 in combination with standard of care (SOC)

• Country None
• organs None
• Specialty None

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE LEBRIKIZUMAB (MILR1444A) IN ADULT PATIENTS WITH ASTHMA WHO ARE NOT TAKING INHALED CORTICOSTEROIDS (MOLLY) The main objectives of this study are as follows; - To evaluate the efficacy of different doses of lebrikizumab compared with placebo as measured by relative change in pre-bronchodilator FEV1. -...

• Country None
• organs None
• Specialty None

A clinical study comparing the effects of chemotherapy plus Avastin to chemotherapy plus Avastin plus a new drug (MEGF0444A) in patients with non-small cell lung cancer who have not received chemotherapy before To evaluate the efficacy of MEGF0444A used in combination with carboplatin + paclitaxel + bevacizumab therapy in patients with advanced or recurrent non-squamous NSCLC, as measured by progression-free...

• Country None
• organs None
• Specialty None

A Study of ARN-810 (GDC-0810) Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Phase Ia: To determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) and assess the safety of single agent GDC-0810 in postmenopausal women with locally advanced or metastat...

• Country None
• organs None
• Specialty None

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Of Xolair (Omaluzimab) In Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Anithistamine Treatment (H1) To evaluate the efficacy of single doses of omalizumab compared with placebo in patients with refractory chronic idiopathic urticaria (CIU) receiving concomitant H1 antihistamine therapy

• Country None
• organs None
• Specialty None

Imaging study in patients with Crohn`s Disease Estudio con técnicas de imagen en pacientes con enfermedad de Crohn To estimate the test-retest reliability (precision) of MRE assessments of CD activity in the small bowel in a global setting Calcular la fiabilidad prueba-reprueba (precisión) de las evaluacione...

• Country None
• organs None
• Specialty None

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma Studie bezpečnosti a účinnosti Bendamustinu oproti Bendamustinu v kombinaci s GA101 u pacientů s non-Hodgkinským lymfomem refrakterním na Rituximab To evaluate clinical benefit in terms of PFS, as assessed by an IRF, for GA101 when used in combination with bendamustine compared with bendamustine alone in patients with indolent NHL refractory to p...

• Country None
• organs None
• Specialty None

A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model To evaluate the reduction in AUC of virus load from the nasopharyngeal mucosa in the MHAA4549A treatment group compared to placebo

• Country None
• organs None
• Specialty None